Innovative cyclic peptide disrupts IL-17RB-MLK4 interaction for targeted pancreatic cancer therapy.

• Tác giả: Wei-Chieh Cheng, Chun-Mei Hu, Ching-Hsuan Huang, Yi-Ling Ko, Jiin Horng Lee, Kuo-Ging Lin, Yung-Chen Lo, Sui-Chih Tien, Dan-Ni Wu, Ying-Ta Wu, Hui-Ming Yu, Lee Zong-You
• Ngôn ngữ: eng
• Thông tin xuất bản: France : Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie , 2025
• Bộ sưu tập: NCBI
• ID: 737715

Tóm tắt

The IL-17B/IL-17RB oncogenic signaling axis promotes pancreatic cancer progression through interaction with mixed-lineage kinase 4 (MLK4). Here, we improved the effectiveness of a therapeutic peptide (TAT-IL17RB